Announced
Completed
Financials
Tags
biopharmaceuticals
Domestic
Friendly
Acquisition
Merger
Pharmaceuticals
Single Bidder
United States
Private
Majority
De-SPAC
Reverse Takeover
Completed
Synopsis
Peak Bio, a clinical-stage biopharmaceutical company, went public via a SPAC merger with Ignyte Acquisition, a blank cheque company, in a $378m deal. “We believe that Peak Bio is now well positioned to succeed in the public markets and look forward to updating the entire investment community on our progress in our differentiated approach in both oncology and rare inflammatory diseases,” Hoyoung Huh, Peak Bio Chairman and Founder.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.